Document is current
Any future updates will be listed below
-
Authors
Dimopoulos, Meletios A. https://orcid.org/0000-0001-8990-3254
Lonial, Sagar https://orcid.org/0000-0002-8322-9323
Chng, Wee-Joo https://orcid.org/0000-0003-2578-8335
Iida, Shinsuke https://orcid.org/0000-0002-4951-960X
Mateos, María-Victoria https://orcid.org/0000-0003-2390-1218
Morgan, Gareth J.
Li, Cong
Byrne, Catriona
Suryanarayan, Kaveri https://orcid.org/0009-0002-8776-1533
Labotka, Richard
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
-
Funding
Funding for this research was provided by:
Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA
- License Information
-
More Information
Article History
Received: 3 June 2025
Revised: 29 August 2025
Accepted: 11 November 2025
First Online: 4 December 2025
Competing interests
: MAD reports being on an advisory council or committee for and receiving honoraria from Amgen, Sanofi, Regeneron, Menarini, Takeda, GlaxoSmithKline, Bristol Myers Squibb, Janssen, Beigene, Swixx, and AstraZeneca. SL reports being on a scientific advisory board for Takeda, Amgen, Novartis, Bristol Myers Squibb, GlaxoSmithKline, Abbvie, Genentech, Pfizer, Regeneron, and Janssen; research support for clinical trials from Novartis, Bristol Myers Squibb, Janssen, and Takeda; and being on the board of directors (with stock) for TG Therapeutics (neurology and autoimmune indications). WJC has received honoraria from Amgen, Takeda, Janssen, Bristol Myers Squibb, GlaxoSmithKline, Sanofi, Pfizer, and Abbvie; and grants or funds from Janssen, Bristol Myers Squibb, Abbvie, and GlaxoSmithKline. SI reports receiving honoraria from Takeda, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Sanofi, Ono, and AstraZeneca; consulting fees from Takeda, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Abbvie, Novartis, AstraZeneca, and GlaxoSmithKline; and grants or funds from Takeda, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Sanofi, Ono, AstraZeneca, Chugai, Shionogi, GlaxoSmithKline, Daiichi Sankyo, Abbvie, Amgen, Otsuka, Alexion, and Novartis. MVM has been on an advisory board or committee for and received honoraria from Johnson & Johnson, Bristol Myers Squibb, Sanofi, GlaxoSmithKline, Pfizer, Abbvie, Kite, Regeneron, Oncopeptides, and Menarini. CL reports employment with Takeda. KS and RL report employment and ownership of stocks and shares with Takeda. GJM, CB, and SVR report no conflicts of interest.
